Trial · NCT05329792
L19IL2/L19TNF in Skin Cancer Patients
NCT05329792, Phase 2, Unknown, Philogen S.p.A.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. L19IL2/L19TNF in Skin Cancer Patients. Trials, record NCT05329792. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05329792
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- L19IL2/L19TNF in Skin Cancer Patients
- NCT number
- NCT05329792
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Philogen S.p.A.
- Conditions
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin, Malignant Adnexal Tumors of the Skin (MATS), Tumors From Cutaneous T-cell Lymphoma (CTCL), Kaposi Sarcoma
- Interventions
- L19IL2/L19TNF
- First posted
- 2022-04-15
- Last updated
- 2023-10-06
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Confirmed best overall response rate (BORR) | Visit will be performed at week 12 | Efficacy of L19IL2/L19TNF measured as Confirmed best overall response rate (BORR) \[Complete Response (CR) + Partial Response (PR)\] for each tumor type measured according to RECIST v1.1 criteria. Confirmation of CR requires histopathological analysis of exeresis specimens for lesions removed by surgery or of biopsies in all other cases. |
| Secondary | Disease control rate (DCR) | Visits will be performed at week 12, week 20, week 28, week 36, week 44 and week 52 | Disease control rate (DCR) \[Complete Response (CR) + Partial Response (PR) + Stable Disease (SD)\] for each tumor type measured according to RECIST v1.1 criteria. |
| Secondary | Local PFS (LPFS) | Visits will be performed at week 12, week 20, week 28, week 36, week 44 and week 52 | Local Progression Free Survival (LPFS) on the treated tumors only |
| Secondary | Progression-free survival (PFS) | Visits will be performed at week 12, week 20, week 28, week 36, week 44 and week 52 | Progression-free survival (PFS), assessed separately in patients who are not resected after curative intention and in patients who undergo secondary surgery (neoadjuvant intention), whatever the RECIST response to treatment, taking into account appearance of new lesions and occurrence of metastases, |
| Secondary | Adverse Events (AE) | From the inclusion in the study (signature of the informed consent form - ICF) until the end of the trial (week 52). | Percentage of Patients in Each Treatment Group with AEs, AEs with CTCAE grade ≥3 |
| Secondary | Serious Adverse Event (SAEs) | From the inclusion in the study (signature of the informed consent form - ICF) until the end of the trial (week 52). | Percentage of Patients in Each Treatment Group with Drug-Related Adverse Events, Serious Adverse Event (SAEs) |
| Secondary | Human anti-fusion protein antibodies (HAFA) | At week 1, at week 4 and at week 12 | Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19IL2 and L19TNF |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38664936 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05329792
GET https://conductscience.org/api/trials/v1/NCT05329792/registered